Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study.

Klil-Drori AJ, Santella C, Tascilar K, Yin H, Aprikian A, Azoulay L.

Drug Saf. 2019 Jun 25. doi: 10.1007/s40264-019-00847-w. [Epub ahead of print]

PMID:
31240687
2.

Effectiveness of interventions for the implementation of thromboprophylaxis in hospitalised patients at risk of venous thromboembolism: an updated abridged Cochrane systematic review and meta-analysis of randomised controlled trials.

Kahn SR, Diendéré G, Morrison DR, Piché A, Filion KB, Klil-Drori AJ, Douketis J, Emed J, Roussin A, Tagalakis V, Morris M, Geerts W.

BMJ Open. 2019 May 24;9(5):e024444. doi: 10.1136/bmjopen-2018-024444.

3.

Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.

Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP).

Haematologica. 2019 Jul;104(7):e293-e295. doi: 10.3324/haematol.2018.211235. Epub 2019 Jan 10. No abstract available.

4.

External Validation of ASPECT (Algorithm for Suspected Pulmonary Embolism Confirmation and Treatment).

Klil-Drori AJ, Prajapati D, Liang Z, Wang M, Toupin D, Alothman L, Lang E, Suryanarayan D, Tagalakis V.

Med Care. 2019 Aug;57(8):e47-e52. doi: 10.1097/MLR.0000000000001055.

PMID:
30608277
5.

Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.

Klil-Drori AJ, Yin H, Azoulay L, Del Corpo A, Harnois M, Gratton MO, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP).

Cancer. 2019 Feb 15;125(4):618-625. doi: 10.1002/cncr.31835. Epub 2018 Nov 13.

PMID:
30423211
6.

Serum organochlorines and non-Hodgkin lymphoma: A case-control study in Israeli Jews and Palestinians.

Klil-Drori AJ, Kleinstern G, Seir RA, Choshen-Cohen L, Abdeen Z, Hussein E, Aqel M, Göen T, Perlman R, Ben-Yehuda D, Paltiel O.

Chemosphere. 2018 Dec;213:395-402. doi: 10.1016/j.chemosphere.2018.09.069. Epub 2018 Sep 14.

PMID:
30241084
7.

Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.

Kahn SR, Morrison DR, Diendéré G, Piché A, Filion KB, Klil-Drori AJ, Douketis JD, Emed J, Roussin A, Tagalakis V, Morris M, Geerts W.

Cochrane Database Syst Rev. 2018 Apr 24;4:CD008201. doi: 10.1002/14651858.CD008201.pub3. Review.

PMID:
29687454
8.

Direct Oral Anticoagulants in End-Stage Renal Disease.

Klil-Drori AJ, Tagalakis V.

Semin Thromb Hemost. 2018 Jun;44(4):353-363. doi: 10.1055/s-0037-1621715. Epub 2018 Jan 10. Review.

PMID:
29320795
9.

Temporal trends in outpatient management of incident pulmonary embolism and associated mortality.

Klil-Drori AJ, Coulombe J, Suissa S, Hirsch A, Tagalakis V.

Thromb Res. 2018 Jan;161:111-116. doi: 10.1016/j.thromres.2017.10.026. Epub 2017 Nov 6.

PMID:
29132688
10.

Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer.

Hicks BM, Klil-Drori AJ, Yin H, Campeau L, Azoulay L.

Epidemiology. 2017 Sep;28(5):712-718. doi: 10.1097/EDE.0000000000000678.

PMID:
28768300
11.

Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.

Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Del Corpo A, Olney HJ, Delage R, Laneuville P, Mollica L, Busque L, Assouline SE; Quebec CML Group.

Am J Hematol. 2017 Oct;92(10):E602-E604. doi: 10.1002/ajh.24838. Epub 2017 Jul 29. No abstract available.

12.

Prolactin-Elevating Antipsychotics and the Risk of Endometrial Cancer.

Klil-Drori AJ, Yin H, Abenhaim HA, du Fort GG, Azoulay L.

J Clin Psychiatry. 2017 Jun;78(6):714-719. doi: 10.4088/JCP.15m10532.

PMID:
28199787
13.

Statins in Multiple Myeloma: Survival Benefit or Immortal Time Bias?

Suissa S, Klil-Drori AJ.

J Clin Oncol. 2017 Apr 20;35(12):1377-1378. doi: 10.1200/JCO.2016.70.9725. Epub 2017 Feb 6. No abstract available.

PMID:
28165910
14.

Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?

Klil-Drori AJ, Azoulay L, Pollak MN.

Nat Rev Clin Oncol. 2017 Feb;14(2):85-99. doi: 10.1038/nrclinonc.2016.120. Epub 2016 Aug 9. Review.

PMID:
27502359
16.

Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer.

Klil-Drori AJ, Tascilar K, Yin H, Aprikian A, Bitton A, Azoulay L.

Am J Epidemiol. 2016 Jul 1;184(1):15-22. doi: 10.1093/aje/kwv307. Epub 2016 Jun 6.

17.

Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.

Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L.

Eur Urol. 2016 Jul;70(1):56-61. doi: 10.1016/j.eururo.2015.06.022. Epub 2015 Jun 29.

PMID:
26138040
18.

15-Lipoxygenases in cancer: a double-edged sword?

Klil-Drori AJ, Ariel A.

Prostaglandins Other Lipid Mediat. 2013 Oct;106:16-22. doi: 10.1016/j.prostaglandins.2013.07.006. Epub 2013 Aug 8. Review.

PMID:
23933488
19.

Activation of coagulation in amniotic fluid during normal human pregnancy.

Sarig G, Klil-Drori AJ, Chap-Marshak D, Brenner B, Drugan A.

Thromb Res. 2011 Nov;128(5):490-5. doi: 10.1016/j.thromres.2011.03.023. Epub 2011 Apr 19.

PMID:
21504838

Supplemental Content

Loading ...
Support Center